SG11201503459SA - Tec family kinase inhibitor adjuvant therapy - Google Patents
Tec family kinase inhibitor adjuvant therapyInfo
- Publication number
- SG11201503459SA SG11201503459SA SG11201503459SA SG11201503459SA SG11201503459SA SG 11201503459S A SG11201503459S A SG 11201503459SA SG 11201503459S A SG11201503459S A SG 11201503459SA SG 11201503459S A SG11201503459S A SG 11201503459SA SG 11201503459S A SG11201503459S A SG 11201503459SA
- Authority
- SG
- Singapore
- Prior art keywords
- kinase inhibitor
- adjuvant therapy
- family kinase
- tec family
- inhibitor adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261722107P | 2012-11-02 | 2012-11-02 | |
US201361785868P | 2013-03-14 | 2013-03-14 | |
PCT/US2013/068132 WO2014071231A1 (en) | 2012-11-02 | 2013-11-01 | Tec family kinase inhibitor adjuvant therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201503459SA true SG11201503459SA (en) | 2015-06-29 |
Family
ID=50628113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201503459SA SG11201503459SA (en) | 2012-11-02 | 2013-11-01 | Tec family kinase inhibitor adjuvant therapy |
Country Status (22)
Country | Link |
---|---|
US (4) | US9717731B2 (en) |
EP (1) | EP2914263A4 (en) |
JP (3) | JP2015536950A (en) |
KR (1) | KR20150080592A (en) |
CN (2) | CN104994858A (en) |
AU (3) | AU2013337663A1 (en) |
BR (1) | BR112015010059A2 (en) |
CA (1) | CA2890111A1 (en) |
CL (1) | CL2015001147A1 (en) |
CR (1) | CR20150242A (en) |
DO (1) | DOP2015000098A (en) |
EA (1) | EA201590822A1 (en) |
HK (1) | HK1214508A1 (en) |
IL (1) | IL238548A0 (en) |
MX (2) | MX2015005633A (en) |
NI (1) | NI201500062A (en) |
PE (1) | PE20151604A1 (en) |
PH (1) | PH12015500985A1 (en) |
SG (1) | SG11201503459SA (en) |
TN (1) | TN2015000170A1 (en) |
TW (1) | TW201427664A (en) |
WO (1) | WO2014071231A1 (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
CN102083800A (en) | 2008-06-27 | 2011-06-01 | 阿维拉制药公司 | Heteroaryl compounds and uses thereof |
US9908884B2 (en) | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
CA2800913C (en) | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
EP3144298A1 (en) | 2010-08-10 | 2017-03-22 | Celgene Avilomics Research, Inc. | Besylate salt of a btk inhibitor |
ES2568680T3 (en) | 2010-10-26 | 2016-05-03 | Mars, Incorporated | Borates as arginase inhibitors |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
RU2644151C2 (en) | 2010-11-01 | 2018-02-08 | Селджен Авиломикс Рисерч, Инк. | Heterocyclic compounds and their application |
JP5957003B2 (en) | 2010-11-10 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | Mutant selective EGFR inhibitor and use thereof |
AR088570A1 (en) | 2011-10-28 | 2014-06-18 | Celgene Avilomics Res Inc | METHODS TO TREAT AN ILLNESS OR DISORDER RELATED TO BRUTON TYROSINE KINASE |
EP2825041B1 (en) | 2012-03-15 | 2021-04-21 | Celgene CAR LLC | Solid forms of an epidermal growth factor receptor kinase inhibitor |
RU2711077C9 (en) | 2012-03-15 | 2020-08-11 | Селджен Кар Ллс | Salts of epidermal growth factor receptor kinase |
BR112015001690A2 (en) | 2012-07-24 | 2017-11-07 | Pharmacyclics Inc | mutations associated with resistance to bruton tyrosine kinase inhibitors (btk) |
BR112015010059A2 (en) | 2012-11-02 | 2017-07-11 | Pharmacyclics Inc | adjuvant therapy with the tec family kinase inhibitor |
EP2935226A4 (en) | 2012-12-21 | 2016-11-02 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
US9561228B2 (en) | 2013-02-08 | 2017-02-07 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
US9421208B2 (en) * | 2013-08-02 | 2016-08-23 | Pharmacyclics Llc | Methods for the treatment of solid tumors |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CN105848680A (en) * | 2013-10-25 | 2016-08-10 | 药品循环有限责任公司 | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy |
US10314842B2 (en) * | 2013-12-02 | 2019-06-11 | Cornell University | Methods for treating B cell proliferative disorders |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
WO2015109391A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
US10076512B2 (en) | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
WO2015187848A1 (en) * | 2014-06-04 | 2015-12-10 | Sampath Deepa | Hdac inhibitor and btk inhibitor combinations |
WO2015192081A1 (en) * | 2014-06-13 | 2015-12-17 | Byrd, John C. | Biomarker for predicting response of cll to treatment with a btk inhibitor |
WO2016010961A1 (en) * | 2014-07-15 | 2016-01-21 | Abbvie Inc. | Enzyme occupancy assay |
EP3171897A4 (en) | 2014-07-25 | 2018-03-21 | Northeastern University | Biopolymer-nanoparticle composite implant for tumor cell tracking |
EP3179858B1 (en) | 2014-08-13 | 2019-05-15 | Celgene Car Llc | Forms and compositions of an erk inhibitor |
WO2016044774A1 (en) * | 2014-09-18 | 2016-03-24 | Pharmacyclics Llc | Dendritic cell based vaccine with bruton's tyrosine kinase inhibitor |
US20180338993A1 (en) * | 2014-12-04 | 2018-11-29 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
WO2016123073A1 (en) | 2015-01-26 | 2016-08-04 | Children's Medical Center Corporation | Treatment of infectious diseases |
US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
IL284985B2 (en) | 2015-02-18 | 2023-03-01 | Enlivex Therapeutics R& D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
WO2016138542A1 (en) * | 2015-02-28 | 2016-09-01 | Cyprus Therapeutics, Inc. | Methods for inhibiting tumors and drug resistance |
EP3284466A4 (en) | 2015-04-13 | 2018-12-05 | Daiichi Sankyo Company, Limited | Treatment method combining mdm2 inhibitor and btk inhibitor |
EP4140492A1 (en) | 2015-04-21 | 2023-03-01 | Enlivex Therapeutics Rdo Ltd | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
HUE054068T2 (en) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Pharmaceutical compositions comprising lonafarnib and ritonavir |
US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
AU2016303659A1 (en) * | 2015-07-31 | 2018-02-22 | Pharmacyclics Llc | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
CN108025013A (en) * | 2015-08-12 | 2018-05-11 | 博尔托拉制药公司 | Match degree for treating myeloma replaces Buddhist nun |
KR20220118559A (en) * | 2015-10-30 | 2022-08-25 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Compositions and methods for inhibiting arginase activity |
ES2959692T3 (en) | 2015-12-04 | 2024-02-27 | Alexion Pharma Inc | Cerdulatinib and venetoclax to treat non-Hodgkin lymphoma |
JP6884155B2 (en) | 2016-02-18 | 2021-06-09 | エンリヴェックス セラピューティクス リミテッド | Combination immunotherapy and cytokine control therapy for cancer treatment |
PT3416675T (en) | 2016-02-19 | 2021-06-14 | Eiger Biopharmaceuticals Inc | Treatment of hepatitis delta virus infection with interferon lambda |
EP3318276A1 (en) | 2016-11-04 | 2018-05-09 | Janssen Biotech, Inc. | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
CN106405086A (en) * | 2016-09-21 | 2017-02-15 | 四川大学华西医院 | Lung cancer screening kit |
EP3534938A2 (en) | 2016-11-03 | 2019-09-11 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and a btk inhibitor |
AU2017368331A1 (en) | 2016-12-03 | 2019-06-13 | Acerta Pharma B.V. | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors |
CN108732280B (en) * | 2017-04-18 | 2022-07-08 | 广东东阳光药业有限公司 | Method for separating and detecting daclatasvir hydrochloride and optical isomer thereof |
WO2019014684A1 (en) * | 2017-07-14 | 2019-01-17 | Ohio State Innovation Foundation | Expansion of immune cells with interleukin-2 inducible t cell kinase inhibiting compounds |
US11897917B2 (en) | 2017-09-27 | 2024-02-13 | The University Of York | Bioconjugation of polypeptides |
CZ2017787A3 (en) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Pharmaceutical compositions containing ibrutinib |
BR112020022185A2 (en) | 2018-05-03 | 2021-02-02 | Juno Therapeutics Inc | combination therapy of a chimeric antigen (car) receptor t cell therapy and a kinase inhibitor |
EP3788035A2 (en) | 2018-05-04 | 2021-03-10 | Portola Pharmaceuticals, Inc. | Solid forms of cerdulatinib |
CN111110685A (en) * | 2018-10-31 | 2020-05-08 | 正大天晴药业集团股份有限公司 | Pharmaceutical composition containing ibrutinib and application thereof |
WO2021050606A1 (en) * | 2019-09-09 | 2021-03-18 | The Children's Hospital Of Philadelphia | Compositions and methods for treatment of disorders associated with clec16a dysfunction or loss |
EP4057807A4 (en) * | 2019-11-11 | 2023-12-27 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animal with human or chimeric genes |
WO2021207716A2 (en) * | 2020-04-10 | 2021-10-14 | Ohio State Innovation Foundation | Methods and composition for treatment of covid-19 illness requiring hospitalization |
EP4161922A1 (en) * | 2020-06-08 | 2023-04-12 | Icahn School of Medicine at Mount Sinai | Use of multi-kinase inhibitors to treat rna virus infections |
WO2023196278A1 (en) * | 2022-04-05 | 2023-10-12 | Corvus Pharmaceuticals, Inc. | Itk inhibitors for increasing th1 cell activity |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
JP3416147B2 (en) | 1996-01-23 | 2003-06-16 | アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド | Regulation of the expression of TH1 / TH2 cytokines by ribavirin and ribavirin analogs in activated T lymphocytes |
EP1254911A1 (en) | 1996-10-16 | 2002-11-06 | ICN Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
US7087236B1 (en) | 1998-09-01 | 2006-08-08 | Merrion Research I Limited | Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof |
CA2345722A1 (en) | 1998-09-28 | 2000-04-06 | Albert Edge | Determining resistance to treatment for hepatitis c virus |
US6824768B2 (en) | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
HUP0200942A3 (en) | 1999-04-19 | 2003-03-28 | Schering Corp | Hcv combination therapy, containing ribavirin in association with antioxidants |
WO2001032210A2 (en) | 1999-10-29 | 2001-05-10 | Pharmacyclics, Inc. | Compositions for treating atheroma and neoplastic tissue |
HUP0300354A3 (en) | 2000-03-09 | 2005-07-28 | Schering Corp | Hiv immune adjuvant therapy |
AU2001259788A1 (en) | 2000-05-18 | 2001-11-26 | Genetics Institute, Llc | Identification and modulationof of a t helper-1 and t helper-2 cells |
WO2002032414A2 (en) | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
US20030103938A1 (en) | 2001-05-09 | 2003-06-05 | Alk-Abello A/S | Pharmaceutical compositions for preventing or treating Th1 and Th2 cell related diseases by modulating the Th1/Th2 ratio |
GB0116249D0 (en) | 2001-07-05 | 2001-08-29 | Imp College Innovations Ltd | Methods |
AU2003251900B2 (en) | 2002-07-15 | 2008-12-18 | President And Fellows Of Harvard College | Methods and compositions for modulating T helper (Th) cell development and function |
EP2572715A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
US20070032457A1 (en) | 2003-05-16 | 2007-02-08 | Blatt Lawrence M | Combination therapy for cancer treatment |
CN102139105A (en) | 2003-09-30 | 2011-08-03 | 特莱索恩儿童健康研究院 | Immunotherapy method |
AU2006310340B2 (en) | 2005-11-04 | 2011-02-10 | Novartis Ag | Changing TH1/TH2 balance in split influenza vaccines with adjuvants |
WO2007059329A2 (en) | 2005-11-16 | 2007-05-24 | Pharmacyclics, Inc. | Methods and compositions for treating cancer |
GB0605521D0 (en) | 2006-03-18 | 2006-04-26 | Isis Innovation | Adjuvant |
US20080131398A1 (en) | 2006-08-21 | 2008-06-05 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
ATE531263T1 (en) | 2006-09-22 | 2011-11-15 | Pharmacyclics Inc | BRUTON TYROSINE KINASE INHIBITORS |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
MX2010005244A (en) | 2007-11-12 | 2010-10-25 | Theraclone Sciences Inc | Compositions and methods for the therapy and diagnosis of influenza. |
GB0805356D0 (en) | 2008-03-25 | 2008-04-30 | Isis Innovation | Vaccine adjuvant composition |
CN102036658A (en) | 2008-05-23 | 2011-04-27 | 香港大学 | Combination therapy for the treatment of influenza |
WO2009149179A2 (en) | 2008-06-03 | 2009-12-10 | Aethlon Medical Inc. | Enhanced antiviral therapy methods and devices |
WO2010034670A2 (en) | 2008-09-26 | 2010-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Host cell kinases as targets for antiviral therapies against hcv infection |
SG172227A1 (en) | 2008-12-18 | 2011-07-28 | Hoffmann La Roche | Biomarkers for hcv treatment response |
WO2010093843A2 (en) | 2009-02-12 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Hcv combination therapies |
KR20120096401A (en) | 2009-04-20 | 2012-08-30 | 제넨테크, 인크. | Adjuvant cancer therapy |
US8299070B2 (en) * | 2009-11-25 | 2012-10-30 | Japan Tobacco Inc. | Indole compounds and pharmaceutical use thereof |
CA2800913C (en) * | 2010-06-03 | 2019-07-23 | Pharmacyclics, Inc. | The use of inhibitors of bruton's tyrosine kinase (btk) |
GB2481611A (en) | 2010-06-30 | 2012-01-04 | Statoil Asa | Test cell for well fluid assessment |
JP2014505666A (en) * | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | Antihypertensive composition and use for cancer treatment |
EP2724156B1 (en) | 2011-06-27 | 2017-08-16 | The Jackson Laboratory | Methods and compositions for treatment of cancer and autoimmune disease |
WO2013036994A1 (en) | 2011-09-16 | 2013-03-21 | Biota Scientific Management Pty Ltd | Compounds for the treatment of hcv |
EP2788020A4 (en) | 2011-12-05 | 2015-04-29 | Immunomedics Inc | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
MA37711A1 (en) | 2012-06-04 | 2017-05-31 | Pharmacyclics Inc | Crystalline forms of a crude tyrosine kinase inhibitor |
BR112015010059A2 (en) | 2012-11-02 | 2017-07-11 | Pharmacyclics Inc | adjuvant therapy with the tec family kinase inhibitor |
-
2013
- 2013-11-01 BR BR112015010059A patent/BR112015010059A2/en not_active Application Discontinuation
- 2013-11-01 TW TW102139881A patent/TW201427664A/en unknown
- 2013-11-01 WO PCT/US2013/068132 patent/WO2014071231A1/en active Application Filing
- 2013-11-01 CN CN201380065469.7A patent/CN104994858A/en active Pending
- 2013-11-01 EP EP13850097.0A patent/EP2914263A4/en not_active Withdrawn
- 2013-11-01 US US14/070,420 patent/US9717731B2/en active Active
- 2013-11-01 PE PE2015000592A patent/PE20151604A1/en not_active Application Discontinuation
- 2013-11-01 CN CN202010271248.7A patent/CN111329989A/en active Pending
- 2013-11-01 JP JP2015540834A patent/JP2015536950A/en active Pending
- 2013-11-01 EA EA201590822A patent/EA201590822A1/en unknown
- 2013-11-01 AU AU2013337663A patent/AU2013337663A1/en not_active Abandoned
- 2013-11-01 MX MX2015005633A patent/MX2015005633A/en unknown
- 2013-11-01 SG SG11201503459SA patent/SG11201503459SA/en unknown
- 2013-11-01 CA CA2890111A patent/CA2890111A1/en not_active Abandoned
- 2013-11-01 KR KR1020157014129A patent/KR20150080592A/en not_active Application Discontinuation
-
2014
- 2014-03-05 US US14/198,559 patent/US20140371241A1/en not_active Abandoned
-
2015
- 2015-04-30 IL IL238548A patent/IL238548A0/en unknown
- 2015-04-30 DO DO2015000098A patent/DOP2015000098A/en unknown
- 2015-04-30 CL CL2015001147A patent/CL2015001147A1/en unknown
- 2015-04-30 NI NI201500062A patent/NI201500062A/en unknown
- 2015-05-04 MX MX2021003018A patent/MX2021003018A/en unknown
- 2015-05-04 PH PH12015500985A patent/PH12015500985A1/en unknown
- 2015-05-04 TN TNP2015000170A patent/TN2015000170A1/en unknown
- 2015-05-08 CR CR20150242A patent/CR20150242A/en unknown
-
2016
- 2016-03-03 HK HK16102454.7A patent/HK1214508A1/en unknown
-
2017
- 2017-07-14 US US15/650,830 patent/US20180071293A1/en not_active Abandoned
-
2018
- 2018-09-21 AU AU2018233032A patent/AU2018233032B2/en not_active Ceased
- 2018-09-25 JP JP2018179447A patent/JP2019031506A/en not_active Ceased
-
2019
- 2019-05-21 US US16/418,590 patent/US20200147084A1/en not_active Abandoned
-
2020
- 2020-07-13 JP JP2020120047A patent/JP2020183413A/en active Pending
- 2020-08-21 AU AU2020220205A patent/AU2020220205A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1214508A1 (en) | Tec family kinase inhibitor adjuvant therapy tec | |
HK1254429A1 (en) | Serine/threonine kinase inhibitors | |
IL265007B (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
HK1208442A1 (en) | Substituted pyrrolopyrimidinylamino-benzothiazolones as mknk kinase inhibitors mknk | |
HK1210174A1 (en) | Serine threonine kinase inhibitors for the treatment of hyperproliferativediseases | |
SG11201503842PA (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
HK1213892A1 (en) | Companion diagnostics for tec family kinase inhibitor therapy tec | |
HK1211574A1 (en) | Serine threonine kinase inhibitors | |
PL2634185T3 (en) | TYK2 kinase inhibitors | |
HK1213252A1 (en) | Bicyclic dihydropyridone kinase inhibitors | |
SG11201500973WA (en) | Amino-quinolines as kinase inhibitors | |
HK1213181A1 (en) | Bicyclic oxa-lactam kinase inhibitors | |
GB201205237D0 (en) | Adjuvant |